Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01519531 | Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy Subjects | PHASE1 | COMPLETED | 48 | — | — | Jan 1, 2012 | Nov 1, 2012 | Dec 6, 2012 | 1 | United States |
| NCT01367873 | Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects | PHASE1 | COMPLETED | 72 | — | — | Jun 1, 2011 | Oct 1, 2011 | Aug 22, 2023 | 1 | United States |
Evaluation will start from predose (Day -1) until the follow-up visit (Day 21)
| Arm | Type | Description |
|---|---|---|
| VIA-3196 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | Multiple, ascending dosing groups (cohorts) will be evaluated. |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Oral, daily-dosing for 14 days; matching number of placebo capsule(s) with active arm |
| VIA-3196 | DRUG | Oral, daily dosing for 14 days |
Inclusion Criteria: * The subject must be willing and able to provide written informed consent. * Healthy, non-smoking, males and females between the ages of 18 and 55 years of age (inclusive). * If female, the subject is of non-child bearing potential (i.e., surgically \[bilateral oophorectomy, hy...